Eyepoint Pharmaceuticals Stock Performance
| EYPT Stock | USD 8.95 0.60 7.19% |
The firm shows a Beta (market volatility) of 3.06, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eyepoint Pharmaceuticals will likely underperform. At this point, Eyepoint Pharmaceuticals has a negative expected return of -0.0115%. Please make sure to confirm Eyepoint Pharmaceuticals' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to decide if Eyepoint Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Eyepoint Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 11.08 | Five Day Return (12.17) | Year To Date Return (58.81) | Ten Year Return (77.10) | All Time Return (97.69) |
Last Split Factor 1:10 | Dividend Date 2020-12-09 | Last Split Date 2020-12-09 |
1 | Acquisition by Hassan Fred of 60000 shares of Eyepoint Pharmaceuticals at 8.16 subject to Rule 16b-3 | 09/03/2024 |
2 | Deerfield Management Company L.P. Series C Grows Stock Holdings in EyePoint Pharmaceuticals, Inc. - MarketBeat | 09/26/2024 |
3 | EyePoint Pharmaceuticals adds US78m to market cap in the past 7 days, though investors from five years ago are still down 62 | 10/15/2024 |
4 | EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 10/16/2024 |
5 | EyePoints Investigational Drug Shows Early And Sustained Improvement Than Regenerons Eylea For Diabetes-Associated Vision Loss | 10/28/2024 |
6 | Really competitive tax breaks keep EyePoint manufacturing in Mass. | 10/29/2024 |
7 | Vanguard Group Incs Strategic Acquisition in EyePoint Pharmaceuticals Inc | 11/05/2024 |
8 | EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments | 11/07/2024 |
9 | Wall Street Analysts See a 175.07 percent Upside in EyePoint Pharmaceuticals Can the Stock Really Move This High | 11/13/2024 |
10 | EYPT Enterprise Value 6.54 Mil - GuruFocus.com | 11/20/2024 |
| Begin Period Cash Flow | 95.6 M |
Eyepoint |
Eyepoint Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 930.00 in Eyepoint Pharmaceuticals on August 24, 2024 and sell it today you would lose (95.00) from holding Eyepoint Pharmaceuticals or give up 10.22% of portfolio value over 90 days. Eyepoint Pharmaceuticals is currently does not generate positive expected returns and assumes 5.8231% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Eyepoint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eyepoint Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eyepoint Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eyepoint Pharmaceuticals, and traders can use it to determine the average amount a Eyepoint Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.002
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EYPT |
Estimated Market Risk
| 5.82 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eyepoint Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eyepoint Pharmaceuticals by adding Eyepoint Pharmaceuticals to a well-diversified portfolio.
Eyepoint Pharmaceuticals Fundamentals Growth
Eyepoint Stock prices reflect investors' perceptions of the future prospects and financial health of Eyepoint Pharmaceuticals, and Eyepoint Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eyepoint Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 379.32 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 12.47 X | ||||
| Revenue | 46.02 M | ||||
| Gross Profit | 26.95 M | ||||
| EBITDA | (69 M) | ||||
| Net Income | (70.8 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.09 X | ||||
| Cash Flow From Operations | 1.88 M | ||||
| Earnings Per Share | (1.99) X | ||||
| Market Capitalization | 569.9 M | ||||
| Total Asset | 355.18 M | ||||
| Retained Earnings | (742.15 M) | ||||
| Working Capital | 281.54 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
About Eyepoint Pharmaceuticals Performance
Assessing Eyepoint Pharmaceuticals' fundamental ratios provides investors with valuable insights into Eyepoint Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Eyepoint Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 307.79 | 323.18 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.27) | (0.28) |
Things to note about Eyepoint Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eyepoint Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eyepoint Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eyepoint Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eyepoint Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 46.02 M. Net Loss for the year was (70.8 M) with profit before overhead, payroll, taxes, and interest of 26.95 M. | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: EYPT Enterprise Value 6.54 Mil - GuruFocus.com |
- Analyzing Eyepoint Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eyepoint Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eyepoint Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eyepoint Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eyepoint Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eyepoint Pharmaceuticals' stock. These opinions can provide insight into Eyepoint Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.